The board of directors for Amylin Pharmaceuticals refuse to defuse proxy puts that would force the company to repay $900 million in outstanding debt if a majority of its 12 directors are replaced in a proxy contest, a shareholder class action claims in Delaware Chancery Court.
Directors could neutralize the situation by approving two election slates, but they refuse to do so because they want to remain in office, the lawsuit claims.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
China's Xi wants bigger global role after Saudi-Iran deal March 13, 2023 -
'It just rang': In crises, US-China hotline goes unanswered February 10, 2023
-
Biden picks Jeff Zients as his next White House chief of staff January 27, 2023 -
Biden says classified document found in 'personal library' January 12, 2023